Chimeric Antigen Receptor T-cells (CAR-T): Looking beyond the hype By Christoph Oldenburg, Dr Markus Thunecke and Dr John Herrmann While Chimeric Antigen Receptor T-cells (CAR-T), have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as a whole… Read More
Phenotypic Drug Discovery: Striving towards the highest level of biological relevance By Dr John Comley Phenotypic drug discovery (PDD) implies screening where the molecular mechanism of action is not assumed and does not require knowledge of the molecular target. As such phenotypic drug discovery is comparable to empirical screening, which… Read More
The California Institute for Regenerative Medicines Human iPSC Initiative By Dr Thomas J. Novak This article discusses large-scale generation of patient-derived induced pluripotent stem cells (iPSCs) to accelerate the understanding of disease biology and drug discovery. In 2012, the California Institute for Regenerative Medicine (CIRM) announced its Human iPSC Initiative,… Read More
When Two Are Not Enough: Lead Optimisation Beyond Matched Pairs By Dr Noel M. O'Boyle, Dr Roger A. Sayle and Dr Matt Segall Lead optimisation projects progress by making successive enhancements to one or more starting structures. This is a classic multi-objective optimisation procedure where the goal is not only… Read More
Managing Data Challenges In The New R&D Environment By Dr Paul Denny-Gouldson The discovery and development of drugs is changing. The realm once dominated by ‘big pharma’ is becoming increasingly fragmented into more agile and flexible consortia. The dramatic change of focus on drug type from small molecule to large… Read More
Share Share Tweet Email The Development of Cell-Based Assays For Pain Drug Discovery The Development of Cell-Based Assays For Pain Drug Discovery By Dr Paul Karila and Dr Charlotta Blom Since the completion of the Human Genome Project and the beginning of the so-called genomics era in the 1990s, a… Read More
Epigenetic Targets: On the verge of becoming a major new category for successful drug research By Dr John Comley Most vendors of epigenetic modification proteins and reagents have enhanced and broadened their offerings in recent years. Of particular note is the increasing range of proteins and binding assays that now… Read More
BioPharma and CROs Collaborating In Early Drug Discovery By Dr John Montana and Cornelis E.C.A. Hop BioPharma and CROs are riding the latest wave - discovery research - together with a vigour and gusto that might have seemed implausible five years ago. How these collaborations are structured, and how well… Read More
Misconduct in the biomedical sciences part 2: detection and prevention By Dr Gerald H. Lushington and Rathnam Chaguturu Discovering safe and effective medicines, one of the greatest gifts to humanity, relies intensely upon the availability of detailed, unassailably accurate biomedical scientific knowledge. The key distinction that separates science from other… Read More
Precise genome editing: the key to a CRISPR drug discovery pipeline? By Dr. J. D. Wrigley, Dr M Maresca, Dr K Birmingham, Dr M Bohlooly-Y and Dr L M. Mayr From the pioneering days of Watson and Crick in 1953, to completion of the human genome project in 2003, advances… Read More
Misconduct in the biomedical sciences part 1: issues and causes By Dr Gerald H. Lushington and Rathnam Chaguturu Science pursues truth. Real advances in biomedical sciences improve our quality of life and save lives, but the path to these advances is cluttered with the distraction of irreproducible results - an… Read More
By Dr Andy Tsun, Jia Li, Joanne Sun, Dr Michael Yu, Dr Yajie Li and Xiaolin Liu In the past decade, China's drug market has been expanding in double-digit percentages. This has brought about a huge increase in local drug makers and has lured multinational pharmaceutical companies to develop, manufacture… Read More
Restucturing Proteomics: The rise of next-generation affinity reagents By Dr Paul Ko Ferrigno & Dr Jane McLeod The ability of antibodies to bind their target proteins with some degree of specificity has elevated them to being among the most useful tools in biology and medicine, with a market value of… Read More
Redesigning Therapeutic Drug Monitoring for the 21st Century By Lewis Couchman Therapeutic drug monitoring services are a vital part of the pathology laboratory’s remit, providing essential clinical information to guide the management and treatment of a wide range of patients, from those with psychiatric disorders to post-transplantation care. King’s College… Read More
Opportunities For Phenotypic Screening In Drug Discovery By David C. Swinney Renewed awareness of the value of phenotypic screening to drug discovery creates many new opportunities to increase drug discovery success and productivity. These opportunities include identification of translational phenotypic biomarkers, development of new assays that translate to human disease… Read More
AstraZeneca's Novel Approach To Monitor Primary DMPK Assay Performance By Dr Claire Landqvist, Brian Middleton, Dr Barry Jones and Dr Charles O’Donnell Drug This article discusses a novel approach by AstraZeneca to monitor primary DMPK assay performance & understand the inter and intra site assay variability. An integral part of… Read More